André Tichelli
Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage.
Sigle J, Holbro A, Lehmann T, Infanti L, Gerull S, Stern M, Tichelli A, Passweg J, Buser A. Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage. Am J Clin Pathol 2015; 144:145-50.
01.07.2015Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage.
01.07.2015Am J Clin Pathol 2015; 144:145-50
Sigle Joerg P, Holbro Andreas, Lehmann Thomas, Infanti Laura, Gerull Sabine, Stern Martin, Tichelli André, Passweg Jakob, Buser Andreas
Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg J, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter J, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:973-80.
02.04.2013Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
02.04.2013Biol Blood Marrow Transplant 2013; 19:973-80
Holbro Andreas, Lehmann Thomas, Girsberger Sabine, Stern Martin, Gambazzi Franco, Lardinois Didier, Heim Dominik, Passweg Jakob R, Tichelli André, Bubendorf Lukas, Savic Spasenija, Hostettler Katrin, Grendelmeier Peter, Halter Joerg P, Tamm Michael
Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial.
Bucher C, Lehmann T, Tichelli A, Tzankov A, Dirnhofer S, Passweg J, Rovó A. Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial. J Clin Pathol 2012; 66:24-8.
26.10.2012Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial.
26.10.2012J Clin Pathol 2012; 66:24-8
Bucher Christoph, Lehmann Thomas, Tichelli André, Tzankov Alexander, Dirnhofer Stephan, Passweg Jakob, Rovó Alicia
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Girsberger S, Karow A, Lundberg P, Dirnhofer S, Lehmann T, Passweg J, Tichelli A, Skoda R, Rovó A. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol 2012; 129:23-5.
19.09.2012JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
19.09.2012Acta Haematol 2012; 129:23-5
Girsberger Sabine, Karow Axel, Lundberg Pontus, Dirnhofer Stephan, Lehmann Thomas, Passweg Jakob R, Tichelli André, Skoda Radek C, Rovó Alicia
A rare case of coinheritance of Hemoglobin H disease and sickle cell trait combined with severe iron deficiency.
Medinger M, Saller E, Harteveld C, Lehmann T, Graf L, Rovó A, Buser A, Passweg J, Tichelli A. A rare case of coinheritance of Hemoglobin H disease and sickle cell trait combined with severe iron deficiency. Hematol Rep 2011; 3:e30.
06.12.2011A rare case of coinheritance of Hemoglobin H disease and sickle cell trait combined with severe iron deficiency.
06.12.2011Hematol Rep 2011; 3:e30
Medinger Michael, Saller Elisabeth, Harteveld Cornelis L, Lehmann Thomas, Graf Lukas, Rovó Alicia, Buser Andreas, Passweg Jakob, Tichelli André
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Schaub F, Lehmann T, Looser R, Hao-Shen H, Tichelli A, Skoda R. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood 2011; 117:2075-6.
10.02.2011Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
10.02.2011Blood 2011; 117:2075-6
Schaub Franz X, Lehmann Thomas, Looser Renate, Hao-Shen Hui, Tichelli André, Skoda Radek C
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda R. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115:2003-7.
08.01.2010Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
08.01.2010Blood 2010; 115:2003-7
Schaub Franz X, Looser Renate, Li Sai, Hao-Shen Hui, Lehmann Thomas, Tichelli André, Skoda Radek C
Aplastic anemia and concomitant autoimmune diseases
Stalder M, Tichelli A, Meyer-Monard S, Buser A, Arber C, Stern M, Rischewski J, Passweg J, Silzle T, Heim D, Halter J, Rovó A, Gratwohl A. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol 2009; 88:659-65.
13.01.2009Aplastic anemia and concomitant autoimmune diseases
13.01.2009Ann Hematol 2009; 88:659-65
Stalder Magnus P, Tichelli André, Meyer-Monard Sandrine, Buser Andreas, Arber Caroline, Stern Martin, Rischewski Johannes, Passweg Jakob, Silzle Tobias, Heim Dominik, Halter Jörg, Rovó Alicia, Gratwohl Alois
Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy
Decker M, Rothermundt C, Holländer G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. The lancet oncology 2006; 7:693-4.
01.08.2006Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy
01.08.2006The lancet oncology 2006; 7:693-4
Decker Michael, Rothermundt Christian, Holländer Georg, Tichelli André, Rochlitz Christoph
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Kralovics R, Cazzola M, Pietra D, Passamonti F, Tichelli A, Tiedt R, Brutsche M, Buser A, Teo S, Skoda R. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106:3374-6.
15.11.2005Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
15.11.2005Blood 2005; 106:3374-6
Kralovics Robert, Cazzola Mario, Pietra Daniela, Passamonti Francesco, Tichelli André, Tiedt Ralph, Brutsche Martin, Buser Andreas S, Teo Soon-Siong, Skoda Radek C
Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia
Lugli A, Tichelli A, Von Juergensonn S, Mach-Pascual S, Borisch B, Tinguely M, Hawle H, Korte W, Hess U, Passweg J, Gratwohl A, Cogliatti S, Ebnoether M, Dirnhofer S. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Hum Pathol 2005; 36:91-100.
01.01.2005Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia
01.01.2005Hum Pathol 2005; 36:91-100
Lugli Alessandro, Tichelli André, Von Juergensonn Silke, Mach-Pascual Sara, Borisch Bettina, Tinguely Marianne, Hawle Hanne, Korte Wolfgang, Hess Urs, Passweg Jakob, Gratwohl Alois, Cogliatti Sergio B., Ebnoether Monika, Dirnhofer Stephan